now 365 harap2 boleh sampai 30 sen this week

Alahai hexcap bilalah kau nak gerak dari 40 sen tu lamanya tdo

Tkasih jatuh setiap hari mudahan minggu depan boleh sampai 35 sen ke 40 sen

Sekarang smua kejar dc lain yg lebih murah ytl dan ytl power mahal sangat

Bilalah kau nak naik wahai velesto keyfield tu naik bukan main cantik lagi..bisnes pun lebih kurang sama kan

Tq everyone for selling pls go down more

JOHOR BAHRU (Jan 11): The agreement to finalise the establishment of the Johor-Singapore Special Economic Zone (JS-SEZ) will be signed by the fourth quarter of this year, said Johor Investment, Trade and Consumer Affairs Committee chairman Lee Ting Han.

He said the agreement containing the details to develop the economic zone will be signed at the Malaysia-Singapore Leaders’ Retreat taking place near the end of 2024.

“Today’s (Thursday) memorandum of understanding (MOU) represents the political will of the two countries’ leaders to ensure that the economic zone will be established. This zone will be implemented next year,” he told reporters after the MOU signing between Malaysia and Singapore on the JS-SEZ here

https://theedgemalaysia.com/node/697050

Today pisang panas gogogogo

In its property sector note released on Monday (Aug 21), RHB IB assigned an “overweight” rating to the market, with “buy” calls for its top picks UEM Sunrise Bhd at a target price (TP) 92 sen, IOI Properties Group Bhd at a TP of RM1.46, and Matrix Concepts Holdings Bhd at RM1.75.

https://theedgemalaysia.com/node/679379?fbclid=IwAR3HXCqpnzOeu8eeg-5s_7KwvJIR4kisAjpHrBqqeJwwcNp_swQvkWpg86g

https://themalaysianreserve.com/2023/04/18/smrt-gets-shareholders-nod-to-transform-into-a-pure-play-iot-solutions-provider/

https://www.freemalaysiatoday.com/category/highlight/2023/02/11/myegs-week-from-hell-as-rm2-3bil-vanishes-from-market-cap/

Tq cosmos this is the 3rd u tlg saya..jatuh balik sy beli lagi yer hehehe

Tolong jatuh banyak sikit nak beli balik dan tambah ni

Ai leform bilalah kau nak bangun ni lama betul tdo

Hrp2 hari ni lkl jatuh ke 37 sen n below

Hrp2 hari ni thp jatuh ke 40 sen n below

USA inflation data akn release pd 10/11 kalau data cantik sangat dan drama sama berulang smua jual IT stok then boleh beli balik murahlah..perlu sabar sikit

Aii susahnya nak lepas 0.495...

Cerita sama tp diulang2 hanya krn dyson kena saman oleh pekerja ata so bukak balik cerita sama nasib2 hehehe

Bagus pls jatuh so can buy back

Tq ata ambik profit dulu nanti dtg balik...

Kena tengok berapa lama KJ ambik utk approve sinopharm..hrp lagi cepat dr yg lama

https://www.theborneopost.com/2021/07/22/cm-sabah-not-buying-vaccines/

So apa macam MOU bulan May kacau ke x ni..

Lepas egm terus tutup ingat jawab soalan online..kalau betul hrp dia jawablah later..

COMPANIES WITH VACCINE DEAL BOOSTERS
-> UCREST BHD

Deal: Procurement of Sputnik V vaccine from two contract manufacturers in China, with capacity to produce between 312 and 960 million doses over 24 months.

Inked MoU with Russian Direct Investment Fund to manage contract manufacturers for the sovereign fund.

Status: The vaccine maker expects to receive approval from WHO within two months, and has to receive approval from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA).


-> HO WAH GENTING BHD

Deal: Entered into joint venture with E-MO Biology Inc for the development of Covid-19 vaccine derived from existing oral poliovirus vaccine.

Status: To commence production, distribution upon the completion of phase IV trial and approval from the US Food and Drug Administration (US FDA).


-> PHARMANIAGA BHD

Deal: One of two companies that entered into Covid-19 vaccine supply agreements with the health ministry.

Entered into a purchase agreement with Sinovac for 14 million doses of ready-to-fill vaccine and to manufacture the doses domestically.

Received request for 7 million doses from state governments and GLCs.

Status: Expected to supply the federal government with 3.8 million Sinovac vaccine doses by end-June.

Expected to receive 10.4 million doses of Sinovac vaccine by end-August.

The group is able to produce 2 million doses a month


-> KANGER INTERNATIONAL BHD

Deal: Entered into an agreement for the dealership and distribution of Sinopharm’s Covid-19 vaccine.

Inked MoU with Sabah state government for the procurement and import of Sinopharm’s vaccine.

Status: Awaiting delivery schedule from vaccine supplier.


-> BINTAI KINDEN CORP BHD

Deal: Entered into a framework agreement for the commercialisation of Generex’s Ii-Key-SARS-CoV-2, for exclusive rights in Malaysia and several other countries in Southeast Asia. As a prerequisite it has to secure a pharmaceutical good distribution practice certification from the NPRA and register the product with the agency.

Status: The submission to NPRA is expected to be done by 2022/2023.

Generex has filed for a trademark application for the vaccine. Announced in January that it was preparing for a new drug application to US FDA.


-> DUOPHARMA BIOTECH BHD

Deal: Entered into an agreement with the Malaysian government for the supply of 6.4 million doses of Russia’s Sputnik V Covid-19 vaccine.

Status: The vaccine maker expects to receive approval from WHO within two months, and has to receive approval from NPRA.


-> SOLUTION GROIUP BHD

Deal: Entered into a registration, manufacturing and commercialisation agreement to market and distribute China’s CanSino Biologics’ Covid-19 vaccine. It will establish a fill-and-finish facility for the vaccine.

Entered into a supply agreement with the health ministry for 3.5 million doses of CanSino’s vaccine.

Status: Received conditional approval from the Drug Control Authority for the vaccine for emergency use.


-> WIDAD GROUP BHD

Deal: To distribute oral-based Covid-19 vaccine developed by US-based Vaxart Inc in Malaysia with Rinani Dynamic Sdn Bhd after obtaining licences and approval from the authorities in Malaysia.

Status: Vaxart to embark on phase II testing in mid-2021, will seek approval from NPRA upon obtaining approval from US FDA.


-> MY EG SERVICES BHD

Deal: Entered into a partnership with SinoPhil Biotech for the provision of a Covid-19 vaccination programme in the Philippines.

Inked letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd for the supply of initial 10 million doses of the latter’s Covid-19 vaccine as soon as the government gives approval for private market vaccination.

Status: Awaiting approval by the Philippine Food and Drug Administration.

Subject to Zhifei’s vaccine meeting all rules, regulations and licensing requirements imposed by NPRA.


-> YONG TAI BHD

Deal: Exclusive distributor for Shenzhen Kangtai Biological Products Co Ltd’s inactivated KConvac vaccine with a period of five years (renewable) for no less than 20 million doses yearly.

Received the first batch of Covid-19 vaccine.

Status: Obtained NPRA’s approval on June 3 for the Clinical Trial Import License. To roll out Phase III clinical trials in Malaysia.

Shot in the arm for firms with Covid vaccine deals
Key challenge is the procurement of the product itself, says MIDF Research head

BY AMIR IMRAN HUSAIN SAFRI
SUNBIZ@THESUNDAILY.COM
PETALING JAYA: As Malaysia’s Covid-19 vaccination programme picks up steam, companies that have ventured into the procurement and distribution of vaccines are set to benefit from such deals in the form of boosters to their income streams.

According to MIDF Research head Imran Yassin, the key challenge will be the procurement of the vaccine itself.

“However, it seems that, for now, this seems manageable. Besides, the varied sources of the vaccines will mitigate some of the concerns as we do not have to rely on one producer, which may lead to bottlenecks and delays in the delivery of vaccines,” he told SunBiz.

As Malaysia grapples with containing the Covid-19 pandemic, an accelerated vaccine rollout has been touted as a viable solution to its woes and set it on the right track towards economic reopening and recovery.

In developed economies such as the US and the UK, inoculation efforts have managed to turn around their struggles with the pandemic and brought them to the path of economic recovery.

The UK has logged an estimated 4.7 million Covid-19 cases to date, out of a population of 66.65 million. Since the rollout of vaccination, the country has eased curbs on certain sectors and sports events are allowed subject to conditions.

In recent weeks, the US has seen its 7-day average of new Covid-19 infections flatten to below 20,000 from a peak of 300,628 on Jan 8 after slightly more than half its population of 332 million have received at least one dose of vaccine.

With such empirical evidence, Imran opined that Malaysia’s economic recovery depends on the success of its vaccination programme. “Should herd immunity be achieved earlier, we believe that the country’s economic recovery will move in tandem and can also be achieved earlier,” he said.

Science, Technology, and Innovation Minister Khairy Jamaluddin, who serves as the National Covid-19 Immunisation Programme (NCIP) coordinating minister, announced on Thursday that the federal government is allowing state governments and private hospitals to purchase vaccines other than those used in the federal programme, provided they are approved by the World Health Organisation (WHO).

He said they could source vaccines from the same suppliers as the federal government, namely Sinovac and BioNtech-Pfizer, although the national vaccination programme’s orders will be fulfilled first.

Apart from Sinovac and BioNtech-Pfizer, WHO has approved AstraZaneca, Sinopharm, Serum Institute of India, Janssen and Moderna vaccines for emergency use.

In addition, to this, the NCIP has increased the number of mega vaccination centres. On June 21, the NCIP included Bukit Jalil Natinal Stadium in its list of mega vaccine centres. The stadium joins Kuala Lumpur Convention Centre, Setia City Convention Centre and three other mega vaccine centres that came online on June 7.

Imran views the efforts to ramp upvaccination in positive light and the immunisation objective is within reach. “The key now is to convince more rakyat to be inoculated, which is a shared responsibility and not just the government’s.”

Hopefully next is Sinopharm

PETALING JAYA: The Drug Control Authority (DCA) of Malaysia has approved the use of the Pfizer-BioNTech Covid-19 vaccine for those aged 12 and above, said Tan Sri Dr Noor Hisham Abdullah.

The Health director-general also said in a statement on Tuesday (June 15) that they gave conditional registration for the use of the CanSino and Johnson & Johnson vaccines, both of which only require one shot of the dose.

Dalam sidang media hari ini, Khairy berkata, selagi vaksin itu sudah diluluskan Bahagian Regulatori Farmasi Negara (NPRA), kerajaan negeri bebas membelinya.

Mcm mana mau discuss kalau NPRA belum approve..

https://www.freemalaysiatoday.com/category/bahasa/tempatan/2021/06/03/kerajaan-negeri-bebas-beli-vaksin-moderna-sinopharm/

Singapore to allow more vaccines approved by WHO

Speaking at the same press conference, Health Minister Ong Ye Kung revealed that the Ministry of Health (MOH) will be opening up access to other Covid-19 vaccines under the Special Access Route (SAR) in order to enhance the overall vaccination coverage for those who are unable to take the Pfizer or Moderna vaccine due to medical conditions, 

This differs from the Pandemic Special Access Route (PSAR), which the Health Science Authority has used to authorise the Pfizer and Moderna vaccines. 

MOH will allow the SAR to be used for the supply of Covid-19 vaccines that have been approved by the World Health Organisation (WHO) to be on their Emergency Use Listing (EUL). 

Such use of the SAR for these unregistered pandemic vaccines will be time-limited, for the duration of the pandemic. These vaccines include Johnson and Johnson, Sinopharm and AstraZenaca, in addition to the Pfizer and Moderna shots. 

These vaccines will be made available through the private healthcare sector, but the doctor administering the vaccine should discuss the risks and benefits of using vaccines not registered or authorised by HSA with the patient

Patients will also need to sign an informed consent form to acknowledge that they have discussed with their doctor and accept all responsibility for the risks. 

The Government will not subsidise vaccines administered under the SAR, and persons vaccinated under the SAR will not be eligible for the Vaccine Injury Financial Assistance Programme for Covid-19 Vaccination (VIFAP). 

“As more data becomes available, MOH will be able to determine if persons vaccinated under the SAR may be eligible for the same exemptions on testing, or public health restrictions, which may be accorded to individuals vaccinated under our national programme,” says MOH.

Tq for panic selling

https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

https://www.astroawani.com/berita-malaysia/majlis-presiden-ph-gesa-kelulusan-vaksin-sinopharm-moderna-dipercepatkan-300160

Hopefully with Sabah assistance approval is faster

really hard to break 0.095 aisshhh

Bumi Armada

More provisions from Bumi Armada?

BUMI Armada Bhd, the service provider to oil and gas companies, has provided for no less than RM5.8bil as impairments for its assets since the financial year 2016. The bulk of the provisioning was taken up at the group level.

If anybody had thought that the company, which is owned by T. Ananda Krishnan, was done with provisioning for its assets, they were proven wrong. In the latest quarter results, the company sunk into the red due to the setting aside RM314mil for impairments for its offshore marine services (OMS) segment.

Bumi Armada has 35 vessels in its OMS segment where the utilisation rate is 56%. Out of the 35 vessels, three are subsea construction (SC) vessels while the rest are offshore service vessels (OSVs).

According to analysts, the provisions are mainly for the SC vessels that are lying idle without any charter in hand since early last year. The SC vessels are in the Caspian Sea where drilling activities have reduced significantly.
Fortunately for Bumi Armada, its floating production, storage and offloading (FPSO) assets are performing well. Bumi Armada wholly owns four FPSOs and co-owns three others.

It has one FPSO asset that is lying idle and up for sale. Fortunately, the company has completely provided for the FPSO asset that was due to be mobilised to an oil field offshore Australia. But there were disagreements and the FPSO Claire has returned to the custody of Bumi Armada. Hence, if any sale happens, it is a pure writeback for Bumi Armada.

The company is looking to dispose of the remaining OSVs because competition is keen and margins are narrow in that particular segment of the oil and gas industry. Even Petronas has urged the local players to consolidate but its calls have largely fallen on deaf ears.

The concern is Bumi Armada would have to provide more impairments as more disposals of OSVs take place.

Towards this end, some analysts have downgraded the stock to as low as 10 sen as they do not see any catalyst for earnings growth and are uncertain if the company has to make more provisions.

tq uncle donald n uncle xi..hrp esk ada lelong for solarvest..

https://www.thesundaily.my/local/cement-makers-agree-not-to-raise-price-LB993085#pk_campaign=MASwpn&pk_kwd=Cement+makers+agree+not+to+raise+price

tq to everyone pls continue sell for the rest of the week...hopefully 60 sen by this Friday

Really hope for panic selling sampai limit down...boleh beli bila amat murah..lelong lelong hehehe...

Ini stock memang bagus..dpt kontrak ka atau good qtr result pun rasanya memang tak akan naik..vele good for long term

Ari ni xkan naiklah mayb tungu minyak 100 dollar baru naik...sapa suka hold hold hold x tau sampai bila bolehlah tambah

Minyak naik again tapi adakah vele vele n sapng akn tdo lagi....abg n adik smua naik

X boleh naik ni...kejap2 0.31 kejap2 0.315...

Jatuhlah wahai azrb mau beli balik ni...

Tq everyone very cheap .keep falling pls...

Yes losses are going down hopefully they can extend their court order with creditors this March